| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 2.58 | 77.9% | 124.3% |
| Total Income | 2.58 | 77.9% | 124.3% |
| Expenditure | 3.09 | 33.2% | 21.6% |
| PBT | — | ||
| Net Profit | -0.15 | 82.3% | 89.2% |
| OPM | -19.84% | 40.88pp | |
| NPM | -5.62% | 53.30pp | |
| EPS | -0.02 | 83.3% | 90.9% |
ZEO ScientifiX Reports Strong Revenue Growth Of 124.6% For Q1 2026
08 Jul 2026 · 8 Jul, 5:36 pm
Summary
ZEO ScientifiX announced exceptional year-over-year revenue growth for the quarter and six months ended April 30, 2026. Revenue for the quarter surged by 124.6% to $2,581,000, while six-month revenue grew 79.9% to $4,027,000, driven by commercial acceleration in its regenerative biologics portfolio. The company maintained strong gross margins around 80.0% and significantly reduced its net loss to $1.0 million for the six-month period. Management highlighted this as an important inflection point, expecting continued expansion opportunities.
Key Highlights
- 1
ZEO ScientifiX reported revenue growth of 124.6% for the quarter ended April 30, 2026, reaching $2,581,000 compared to $1,149,000 in the prior year period.
- 2
For the six months ended April 30, 2026, revenue increased by 79.9% to $4,027,000, up from $2,239,000 in the same period of 2025.
- 3
The company maintained gross margins of approximately 80.0% during the six-month periods ended April 30, 2026 and 2025.
- 4
Net loss was reduced to approximately $1.0 million for the six months ended April 30, 2026, a significant improvement from a net loss of approximately $2.6 million in the comparable 2025 period.
- 5
The strong performance is attributed to increased demand for stem-cell-focused biologic products, continued growth in allogenic product sales, and expanded physician adoption.
Management Comments
Ian Bothwell
Our results for the recently reported six months ended April 30, 2026 marks an important inflection point for ZEO ScientifiX. We are seeing meaningful growth momentum across the business as more physicians look to ZEO as a trusted supplier and educational partner for their regenerative medicine. Our team has worked relentlessly on safety, research and quality, all helping to expand awareness, strengthen relationships, and support the safe and responsible adoption of stem-cell-focused and allogenic biologic technologies. We expect the foundation we are building today will provide ZEO with continued opportunities to expand.
Informational and educational content only. Not investment advice.